WO2009028543A1 - 置換ピラゾール誘導体 - Google Patents

置換ピラゾール誘導体 Download PDF

Info

Publication number
WO2009028543A1
WO2009028543A1 PCT/JP2008/065286 JP2008065286W WO2009028543A1 WO 2009028543 A1 WO2009028543 A1 WO 2009028543A1 JP 2008065286 W JP2008065286 W JP 2008065286W WO 2009028543 A1 WO2009028543 A1 WO 2009028543A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
bonding hand
atom serving
serving
pyrazole derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/065286
Other languages
English (en)
French (fr)
Inventor
Mitsuhiro Ito
Tomohiko Suzaki
Satoshi Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP08828418A priority Critical patent/EP2194045A4/en
Priority to CN200880114151A priority patent/CN101842357A/zh
Priority to AU2008292429A priority patent/AU2008292429A1/en
Priority to JP2009530148A priority patent/JPWO2009028543A1/ja
Priority to BRPI0816095-3A2A priority patent/BRPI0816095A2/pt
Priority to MX2010002266A priority patent/MX2010002266A/es
Priority to CA2697663A priority patent/CA2697663A1/en
Priority to US12/675,748 priority patent/US20100227846A1/en
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Priority to EA201070323A priority patent/EA201070323A1/ru
Publication of WO2009028543A1 publication Critical patent/WO2009028543A1/ja
Priority to TNP2010000091A priority patent/TN2010000091A1/fr
Anticipated expiration legal-status Critical
Priority to MA32720A priority patent/MA31714B1/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

　新規ピラゾール誘導体およびそれを含有するアンドロゲン受容体拮抗剤の提供。式（Ｉ’） 〔式中、Ｒ１は、水素原子、炭素原子を介する基、窒素原子を介する基、酸素原子を介する基、または硫黄原子を介する基；Ｒ２は、シアノを有するフェニル基（本フェニル基はシアノ以外の置換基をさらに有していてもよい）；Ｒ３は、水素原子、炭素原子を介する基、窒素原子を介する基、酸素原子を介する基、または硫黄原子を介する基；Ｒ４は、置換基を有していてもよい環状基；およびＸは、置換基を有していてもよいメチレン、またはＣＯを示す。〕で表される化合物、またはその塩。
PCT/JP2008/065286 2007-08-30 2008-08-27 置換ピラゾール誘導体 Ceased WO2009028543A1 (ja)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA2697663A CA2697663A1 (en) 2007-08-30 2008-08-27 Substituted pyrazole derivative
AU2008292429A AU2008292429A1 (en) 2007-08-30 2008-08-27 Substituted pyrazole derivative
JP2009530148A JPWO2009028543A1 (ja) 2007-08-30 2008-08-27 置換ピラゾール誘導体
BRPI0816095-3A2A BRPI0816095A2 (pt) 2007-08-30 2008-08-27 Composto ou um sal do mesmo, pró-droga, agente farmacêutico, métodos para antagonizar um receptor de androgênio e para prevenir / tratar cãncer, e, uso do composto ou uma pró-droga do mesmo.
MX2010002266A MX2010002266A (es) 2007-08-30 2008-08-27 Derivados de pirazol sustituidos.
EP08828418A EP2194045A4 (en) 2007-08-30 2008-08-27 Substituted pyrazole derivative
CN200880114151A CN101842357A (zh) 2007-08-30 2008-08-27 取代的吡唑衍生物
US12/675,748 US20100227846A1 (en) 2007-08-30 2008-08-27 Substituted pyrazole derivative
EA201070323A EA201070323A1 (ru) 2007-08-30 2008-08-27 Замещенное производное пиразола
TNP2010000091A TN2010000091A1 (en) 2007-08-30 2010-02-23 Substituted pyrazole derivative
MA32720A MA31714B1 (fr) 2007-08-30 2010-03-26 Derive de pyrazole substitue

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-224910 2007-08-30
JP2007224910 2007-08-30

Publications (1)

Publication Number Publication Date
WO2009028543A1 true WO2009028543A1 (ja) 2009-03-05

Family

ID=40387261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/065286 Ceased WO2009028543A1 (ja) 2007-08-30 2008-08-27 置換ピラゾール誘導体

Country Status (20)

Country Link
US (2) US20090270359A1 (ja)
EP (1) EP2194045A4 (ja)
JP (1) JPWO2009028543A1 (ja)
KR (1) KR20100046275A (ja)
CN (1) CN101842357A (ja)
AR (1) AR068813A1 (ja)
AU (1) AU2008292429A1 (ja)
BR (1) BRPI0816095A2 (ja)
CA (1) CA2697663A1 (ja)
CL (1) CL2008002521A1 (ja)
CO (1) CO6190530A2 (ja)
DO (1) DOP2010000068A (ja)
EA (1) EA201070323A1 (ja)
EC (1) ECSP10010060A (ja)
MA (1) MA31714B1 (ja)
MX (1) MX2010002266A (ja)
PE (1) PE20090610A1 (ja)
TN (1) TN2010000091A1 (ja)
TW (1) TW200913993A (ja)
WO (1) WO2009028543A1 (ja)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011051540A1 (en) 2009-10-27 2011-05-05 Orion Corporation Androgen receptor modulating compounds
WO2012053630A1 (ja) 2010-10-22 2012-04-26 アステラス製薬株式会社 変異アンドロゲン受容体拮抗薬
CN102481294A (zh) * 2009-09-11 2012-05-30 拜耳医药股份有限公司 作为抗癌药物的取代(杂芳基甲基)乙内酰硫脲
WO2012127441A1 (en) 2011-03-23 2012-09-27 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
WO2012143599A1 (en) 2011-04-21 2012-10-26 Orion Corporation Androgen receptor modulating carboxamides
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
JP2014125430A (ja) * 2012-12-25 2014-07-07 Dow Corning Toray Co Ltd イミド基含有有機ケイ素化合物の製造方法
US9000154B2 (en) 2010-10-19 2015-04-07 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
JP2017525700A (ja) * 2014-08-15 2017-09-07 ヤンセン ファーマシューティカルズ，インコーポレーテッド ピラゾール類
JP2020516672A (ja) * 2017-04-18 2020-06-11 セルジーン クオンティセル リサーチ，インク． 治療用化合物
CN111499539A (zh) * 2020-04-20 2020-08-07 南昌大学 一种以芳基羧酸为原料的芳基氰化物合成方法
JP2021024798A (ja) * 2019-08-02 2021-02-22 株式会社デ・ウエスタン・セラピテクス研究所 エチルアニリノトルエンスルホン酸誘導体の製造方法
JP2023539034A (ja) * 2020-08-04 2023-09-13 プレシジョン・バイオ－セラピューティクス・エッセ・エッレ・エッレ 胆汁酸受容体及びロイコトリエンシステイニル受容体の選択的及び／又は二重調節剤としてのキノリン化合物
WO2024013690A1 (en) * 2022-07-15 2024-01-18 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole triazole compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
RU2858542C2 (ru) * 2022-07-15 2026-03-18 Чонг Кун Данг Фармасьютикал Корп. Соединения 1,3,4-оксадиазолтриазола в качестве ингибитора гистондеацетилазы 6 и фармацевтическая композиция, содержащая их

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102056907B (zh) * 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
JP6130383B2 (ja) 2011-09-30 2017-05-17 エンドゥ ファーマシューティカルズ，インコーポレイティド ピリジン誘導体
JP6105594B2 (ja) 2011-09-30 2017-03-29 エンドゥ ファーマシューティカルズ，インコーポレイティド 癌処置用ｃｙｐ１７阻害剤としてのイミダゾール誘導体
EP3180329B1 (en) 2014-08-15 2020-03-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
MX2018000352A (es) 2015-07-09 2018-08-15 Janssen Pharmaceutica Nv 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
DE102015011861B4 (de) 2015-09-10 2018-03-01 Rudolf Schindler Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren
KR20180108822A (ko) 2016-02-10 2018-10-04 얀센 파마슈티카 엔.브이. Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
AU2017278314B2 (en) 2016-06-10 2022-06-30 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806719B2 (en) 2016-06-10 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
CN107903213A (zh) * 2017-09-28 2018-04-13 山东大学 5‑甲基‑1h‑吡唑衍生物及其制备方法和应用
EP3774732A4 (en) 2018-04-04 2022-02-09 Janssen Pharmaceutica NV PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
CN108676001A (zh) * 2018-06-12 2018-10-19 江西师范大学 一种3-取代-5-异噁唑基-4-取代-1-1,2,3-三氮唑基甲烷化合物
US12202815B2 (en) 2018-09-05 2025-01-21 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
AU2020291188A1 (en) 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Substituted heteroaromatic Pyrazolo-pyridines and their use as GluN2B receptor modulators
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用
US20220324860A1 (en) 2019-06-14 2022-10-13 Janssen Pharmaceutica Nv SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
BR112021025132A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Carbamatos de piridina e seu uso como moduladores do receptor glun2b
SG11202112407PA (en) 2019-06-14 2021-12-30 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
AU2020290772A1 (en) 2019-06-14 2022-01-06 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators
EP3983413A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056785A1 (en) * 1997-06-12 1998-12-17 Sumitomo Pharmaceuticals Co., Ltd. Pyrazole derivatives
WO2003057669A1 (fr) * 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Antagonistes du recepteur androgene
WO2006064944A1 (en) * 2004-12-14 2006-06-22 Takeda Pharmaceutical Company Limited Substituted pyrrole derivative
JP2007332053A (ja) * 2006-06-13 2007-12-27 Takeda Chem Ind Ltd 置換ピロール誘導体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US401275A (en) * 1889-04-09 Wagon-tire
US20040229900A1 (en) * 1999-06-16 2004-11-18 Astrazeneca Ab Bispidine compounds useful in the treatment of cardiac arrythmias
SE0002603D0 (sv) * 2000-07-07 2000-07-07 Astrazeneca Ab New compounds
EP2048142A3 (en) * 2001-04-26 2009-04-22 Eisai R&D Management Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
CA2462289C (en) * 2001-10-04 2010-02-23 Nicholas D. Cosford Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
JP4286146B2 (ja) * 2001-12-18 2009-06-24 メルク エンド カムパニー インコーポレーテッド メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピラゾール系調節剤
EP1458708B1 (en) * 2001-12-18 2007-09-26 Merck & Co., Inc. Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
EP1458385A4 (en) * 2001-12-19 2005-12-21 Merck & Co Inc METABOTROPIC GLUTAMATE RECEPTOR 5-HETEROARYL-SUBSTITUTED IMIDAZOLE MODULATORS
JP4357965B2 (ja) * 2001-12-21 2009-11-04 メルク エンド カムパニー インコーポレーテッド メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピロールモジュレーター
US7482366B2 (en) * 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US7998986B2 (en) * 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
JP2005532291A (ja) * 2002-04-12 2005-10-27 ファイザー株式会社 抗炎症薬および鎮痛薬としてのピラゾール化合物
US20040142978A1 (en) * 2002-12-12 2004-07-22 Pharmacia Corporation Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
US20040127519A1 (en) * 2002-12-12 2004-07-01 Pharmacia Corporation Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
US20040127511A1 (en) * 2002-12-12 2004-07-01 Pharmacia Corporation Tricyclic aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
US7880001B2 (en) * 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
WO2005111003A1 (en) * 2004-04-29 2005-11-24 Abbott Laboratories Amino-tetrazoles analogues and methods of use
AU2007234408B2 (en) * 2006-04-04 2011-05-19 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as HIF modulators
CN101790526A (zh) * 2007-06-08 2010-07-28 雅培制药有限公司 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
US20090270361A1 (en) * 2008-03-26 2009-10-29 Takeda Pharmaceutical Company Limited Substituted pyrazole derivatives and use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056785A1 (en) * 1997-06-12 1998-12-17 Sumitomo Pharmaceuticals Co., Ltd. Pyrazole derivatives
WO2003057669A1 (fr) * 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Antagonistes du recepteur androgene
WO2006064944A1 (en) * 2004-12-14 2006-06-22 Takeda Pharmaceutical Company Limited Substituted pyrrole derivative
JP2007332053A (ja) * 2006-06-13 2007-12-27 Takeda Chem Ind Ltd 置換ピロール誘導体

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481294A (zh) * 2009-09-11 2012-05-30 拜耳医药股份有限公司 作为抗癌药物的取代(杂芳基甲基)乙内酰硫脲
US11046713B2 (en) 2009-10-27 2021-06-29 Orion Corporation Androgen receptor modulating compounds
EP3056485A1 (en) 2009-10-27 2016-08-17 Orion Corporation Androgen receptor modulating compounds
EP3885340A1 (en) 2009-10-27 2021-09-29 Orion Corporation Androgen receptor modulating compounds
WO2011051540A1 (en) 2009-10-27 2011-05-05 Orion Corporation Androgen receptor modulating compounds
US9657003B2 (en) 2009-10-27 2017-05-23 Orion Corporation Androgen receptor modulating compounds
US10711013B2 (en) 2009-10-27 2020-07-14 Orion Corporation Androgen receptor modulating compounds
EP3369732A1 (en) 2009-10-27 2018-09-05 Orion Corporation Androgen receptor modulating compounds
EP2754656A1 (en) 2009-10-27 2014-07-16 Orion Corporation Androgen receptor modulating compounds
US10118933B2 (en) 2009-10-27 2018-11-06 Orion Corporation Androgen receptor modulating compounds
US8975254B2 (en) 2009-10-27 2015-03-10 Orion Corporation Androgen receptor modulating compounds
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9000154B2 (en) 2010-10-19 2015-04-07 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
WO2012053630A1 (ja) 2010-10-22 2012-04-26 アステラス製薬株式会社 変異アンドロゲン受容体拮抗薬
US10092565B2 (en) 2011-03-23 2018-10-09 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
US9464079B2 (en) 2011-03-23 2016-10-11 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
WO2012127441A1 (en) 2011-03-23 2012-09-27 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
WO2012143599A1 (en) 2011-04-21 2012-10-26 Orion Corporation Androgen receptor modulating carboxamides
US8921378B2 (en) 2011-04-21 2014-12-30 Orion Corporation Androgen receptor modulating carboxamides
JP2014511895A (ja) * 2011-04-21 2014-05-19 オリオン コーポレーション アンドロゲン受容体調節カルボキシアミド
JP2014125430A (ja) * 2012-12-25 2014-07-07 Dow Corning Toray Co Ltd イミド基含有有機ケイ素化合物の製造方法
JP2017525700A (ja) * 2014-08-15 2017-09-07 ヤンセン ファーマシューティカルズ，インコーポレーテッド ピラゾール類
USRE49517E1 (en) 2014-08-15 2023-05-02 Janssen Pharmaceuticals, Inc. Pyrazoles
JP2020516672A (ja) * 2017-04-18 2020-06-11 セルジーン クオンティセル リサーチ，インク． 治療用化合物
US11890275B2 (en) 2017-04-18 2024-02-06 Celgene Quanticel Research, Inc. Therapeutic compounds
JP2021024798A (ja) * 2019-08-02 2021-02-22 株式会社デ・ウエスタン・セラピテクス研究所 エチルアニリノトルエンスルホン酸誘導体の製造方法
JP7288665B2 (ja) 2019-08-02 2023-06-08 株式会社デ・ウエスタン・セラピテクス研究所 エチルアニリノトルエンスルホン酸誘導体の製造方法
CN111499539B (zh) * 2020-04-20 2022-10-11 南昌大学 一种以芳基羧酸为原料的芳基氰化物合成方法
CN111499539A (zh) * 2020-04-20 2020-08-07 南昌大学 一种以芳基羧酸为原料的芳基氰化物合成方法
JP2023539034A (ja) * 2020-08-04 2023-09-13 プレシジョン・バイオ－セラピューティクス・エッセ・エッレ・エッレ 胆汁酸受容体及びロイコトリエンシステイニル受容体の選択的及び／又は二重調節剤としてのキノリン化合物
JP7641358B2 (ja) 2020-08-04 2025-03-06 プレシジョン・バイオ－セラピューティクス・エッセ・エッレ・エッレ 胆汁酸受容体及びロイコトリエンシステイニル受容体の選択的及び／又は二重調節剤としてのキノリン化合物
WO2024013690A1 (en) * 2022-07-15 2024-01-18 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole triazole compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
RU2858542C2 (ru) * 2022-07-15 2026-03-18 Чонг Кун Данг Фармасьютикал Корп. Соединения 1,3,4-оксадиазолтриазола в качестве ингибитора гистондеацетилазы 6 и фармацевтическая композиция, содержащая их

Also Published As

Publication number Publication date
TN2010000091A1 (en) 2011-09-26
ECSP10010060A (es) 2010-04-30
EP2194045A4 (en) 2011-09-21
AU2008292429A1 (en) 2009-03-05
MX2010002266A (es) 2010-03-25
CO6190530A2 (es) 2010-08-19
US20100227846A1 (en) 2010-09-09
BRPI0816095A2 (pt) 2015-03-03
PE20090610A1 (es) 2009-06-11
EA201070323A1 (ru) 2010-10-29
US20090270359A1 (en) 2009-10-29
EP2194045A1 (en) 2010-06-09
DOP2010000068A (es) 2010-03-15
MA31714B1 (fr) 2010-09-01
KR20100046275A (ko) 2010-05-06
CA2697663A1 (en) 2009-03-05
CN101842357A (zh) 2010-09-22
CL2008002521A1 (es) 2009-11-20
AR068813A1 (es) 2009-12-09
JPWO2009028543A1 (ja) 2010-12-02
TW200913993A (en) 2009-04-01

Similar Documents

Publication Publication Date Title
TN2010000091A1 (en) Substituted pyrazole derivative
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
WO2008114817A1 (ja) 新規なアデニン化合物
WO2008126889A1 (ja) ヒドラジド化合物及びそれを含有する有害節足動物防除剤
TW200510381A (en) Novel 2-pyridinecarboxamide derivatives
PH12012501711A1 (en) [5,6] heterocyclic compound
WO2005099688A3 (en) Cyclic compounds
MY154772A (en) Harmful arthropod control composition, and fused heterocyclic compound
WO2008126890A1 (ja) ヒドラジド化合物およびそれを含有する有害節足動物防除剤
WO2008096829A1 (ja) ３環系化合物
SG162805A1 (en) Pyrazine derivatives useful as adenosine receptor antagonists
WO2006116412A3 (en) Fused heterocyclic compounds
WO2009057784A1 (ja) 複素環化合物
WO2010013567A1 (ja) アミド誘導体、該アミド誘導体を含有する有害生物防除剤および有害生物の防除方法
WO2008126901A1 (ja) 含窒素複素環化合物およびそれを含有する医薬組成物
WO2008155668A3 (en) Heteroarylamide pyrimidone compounds
WO2009063990A1 (ja) ベンズアゼピノン化合物
TW200738667A (en) Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof
WO2008120754A1 (ja) ピコリン酸アミド化合物
WO2009095792A3 (en) Substituted heteroarylamide diazepinopyrimidone derivatives
MX2010001566A (es) Derivado de aminopirazolamida.
WO2008129966A1 (ja) 有害生物防除組成物
WO2008139845A8 (ja) 新規アミド誘導体
TW200606152A (en) Piperidine compound and process for preparing the same
WO2008117871A1 (ja) 含窒素レドックス触媒

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 1001058

Country of ref document: KE

WWE Wipo information: entry into national phase

Ref document number: 200880114151.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08828418

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009530148

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010020258

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 204095

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2697663

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/002266

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12675748

Country of ref document: US

Ref document number: 12010500461

Country of ref document: PH

Ref document number: 2008828418

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008292429

Country of ref document: AU

Ref document number: 1618/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 584086

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: DZP2010000153

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 201011331

Country of ref document: CR

Ref document number: CR2010-011331

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 20107006668

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 10036555

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: PI 2010000890

Country of ref document: MY

Ref document number: 201070323

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 11746

Country of ref document: GE

ENP Entry into the national phase

Ref document number: 2008292429

Country of ref document: AU

Date of ref document: 20080827

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0816095

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100226